Skip to main content
Emergent BioSolutions Inc. logo

Emergent BioSolutions Inc. — Investor Relations & Filings

Ticker · EBS ISIN · US29089Q1058 LEI · 549300YW6TUOX8BE5103 US Manufacturing
Open in API
Filings indexed 1,264 across all filing types
Latest filing 2012-01-03 Regulatory Filings
Country US United States of America
Listing US EBS

About Emergent BioSolutions Inc.

https://emergentbiosolutions.com/

Emergent BioSolutions Inc. is a life sciences company specializing in solutions for public health threats. The company develops, manufactures, and delivers medical countermeasures for national security and public health preparedness, addressing threats such as anthrax, smallpox, botulism, and Ebola. In addition to its biodefense portfolio, Emergent provides commercial products for endemic health crises, notably the opioid epidemic. The company also offers contract development and manufacturing services through strategic partnerships, leveraging its specialized capabilities to support biopharmaceutical innovators, governments, and non-governmental organizations.

Recent filings

Filing Released Lang Actions
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filing with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a contract modification with the Biomedical Advanced Research and Development Authority, extending the contract period and delivery dates. There are no financial statements or detailed financial data presented, nor is this an annual or quarterly report. The document is not a report publication announcement but a regulatory filing informing about a material contract event. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is short and focused on a specific event, consistent with an 8-K filing.
2012-01-03 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the termination of a material definitive agreement between Emergent BioSolutions Inc. and Abbott Biotherapeutics Corp. It details the termination notice, obligations, and background of the agreement. There are no financial statements or detailed financial performance data, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a call transcript, earnings release, or any other report type. The document is an announcement of a significant corporate event related to contract termination, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories. The document length is about 4862 characters, which is sufficient for a full filing rather than a brief announcement. Therefore, the classification is RNS with high confidence.
2011-12-28 English
8-K Filing
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The content specifically announces the retirement of the CEO and the appointment of a new CEO, along with related compensation details. This fits the category of announcements regarding changes in the company's board of directors or senior management. The document is not a full annual or quarterly report, nor is it an earnings release or other financial report. Therefore, it is best classified as Board/Management Information (MANG). The document length is 4079 characters, which is consistent with a detailed announcement rather than a brief notice or a full report.
2011-12-22 English
8-K Filing
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details amendments to the Senior Management Severance Plan, including changes to bonus definitions and severance terms for a named executive. The key section is Item 5.02, which relates to the departure, election, or appointment of directors or officers and compensatory arrangements. This matches the description of Board/Management Information filings, which cover announcements of changes in the company's board or senior management and related arrangements. The document is relatively short (3264 characters) and does not contain financial statements or detailed financial data, so it is not an Annual Report or Interim Report. It is not a proxy solicitation or remuneration report but rather an announcement of management-related changes. Therefore, the appropriate classification is MANG (Board/Management Information).
2011-12-22 English
8-K Filing
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on the adoption of a severance plan for senior management, detailing terms and conditions related to employment termination and benefits. This is an announcement related to changes in senior management arrangements rather than a full financial report, earnings release, or other report types. The key section is Item 5.02, which pertains to departure or appointment of directors or officers and compensatory arrangements. Therefore, this filing fits best under the category of Board/Management Information (MANG). The document length is substantial and contains detailed information about management compensation plans, not just a brief announcement or certification, supporting a high confidence classification as MANG.
2011-11-14 English
10-Q Filing
Interim / Quarterly Report Q3 2011
2011-11-04 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.